Twenty-nine children with diffuse intrinsic pontine glioma face halted research after a pediatric brain tumor consortium shuttered its operations in September 2026, according to nytimes.com.
The closure ended coordinated clinical trials across multiple institutions, leaving families searching for alternative options as researchers abandon active studies.
One of the paused trials, designated PBTC-059 and led by researchers at Texas Children’s Hospital in Houston, was exploring the safety of CAR-T therapy for patients with ependymoma, nytimes.com reported. Another trial, PBTC-N14 at Memorial Sloan Kettering, was closed entirely before finishing its evaluation of whether cerebral spinal fluid could replace invasive brain biopsies, according to nytimes.com.
“Everyone thought it was a good study, and tried to answer a good question, but it did not finish answering that question,” Matthias Karajannis told nytimes.com.
The consortium ended in September 2026 during a weekly video meeting that carried a funereal tone, nytimes.com reported.
“I felt the loss of hope and opportunity for the parents and the patients,” Mark Dunkel told nytimes.com.
“I guess I never really thought that this was my fault, but I did feel like as the captain of the ship, I let down a lot of people,” Dunkel told nytimes.com.
While institutional trials halt, individual families continue pursuing experimental avenues for young patients. In Stanford, Kentucky, 3-year-old Bowen Pennington has been battling diffuse intrinsic pontine glioma since his diagnosis in late 2025, LEX 18 News reported.

“There’s a one percent chance of survival,” Cierra Pennington told LEX 18 News. “We’ve kind of leaned on the fact it’s not zero. That’s the main goal. It’s not zero.”
Bowen is scheduled for a brain tissue biopsy followed by radiation to identify mutations that might qualify him for clinical trials, LEX 18 News reported. His family is also looking toward a potential future clinical trial in California involving an aggressive cancer similar to DIPG, LEX 18 News reported.
“Our main goal is to find a mutation that matches a clinical trial that can help prolong his life or even shrink his tumor,” Pennington told LEX 18 News.
Grassroots organizations continue to direct funds toward early-stage research despite the closure of large consortia. Keith Desserich received a call from Dunkel in late August 2025 delivering news of the impending institutional cuts, nytimes.com reported.
Desserich and his wife, Brooke, founded The Cure Starts Now in 2007 following the death of their 6-year-old daughter, Elena, from DIPG, nytimes.com reported. Volunteer families collect donations through 5K runs and bowling nights to fund promising brain tumor studies, nytimes.com reported.
The consortium ended operations in September 2026 following a final weekly video meeting, halting active studies such as PBTC-059 and PBTC-N14, according to nytimes.com.
Researchers at Texas Children’s Hospital in Houston were exploring the safety of CAR-T therapy for ependymoma in trial PBTC-059, while Memorial Sloan Kettering researchers evaluated cerebral spinal fluid in trial PBTC-N14, nytimes.com reported.
Families such as the Penningtons in Stanford, Kentucky, are seeking individual biopsies to identify genetic mutations that match active clinical trials in other states, LEX 18 News reported.
Related reading